Orrin Hatch: “support for the passage of H.R. 810 is not limited to the not-for-profit sector. While it is sometimes typical for the…”

“support for the passage of H.R. 810 is not limited to the not-for-profit sector. While it is sometimes typical for the private sector to keep out of some controversial issues, this is not the case with stem cell research. Last week, I received a letter of support for H.R. 810 from the Biotechnology Industry Organization. BIO represents more than 1,100 biotechnology companies, state biotechnology centers, and academic institutions. The BIO letter notes: Expanded support of embryonic stem cell research could also go a long way toward reducing the time and expense needed to develop drugs because new chemical or biological compounds meant to treat diseases could be tested in specific human cells prior to their use in live human beings. Mr. President, I ask unanimous consent to have printed in the Record the July 12, 2006, letter from BIO calling for passage of H.R. 810. There being no objection, the material was ordered to be printed in the Record, as follows: Biotechnology Industry Organization, Washington, DC, July 12, 2006. Hon. Orrin Hatch, U.S. Senate, Washington, DC. Dear Senator Hatch: As President & CEO of the Biotechnology Industry Organization (BIO), I am writing to express BIO's support for H.R. 810, the Stem Cell Research Enhancement Act. Other stem cell legislation being debated by the Senate has merit, but only H.R.…”